Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Genitourinary (Nonprostate) Cancer

Type: Oral Abstract Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Arie Crown Theater

Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

Kidney Cancer

Genitourinary (Nonprostate) Cancer

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr 4508)

Author(s): Arnaud Mejean, Simon Thezenas, Christine Chevreau, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Herve Lang, Laurent Guy, Gwenaelle Gravis, Frederic Rolland, Claude Linassier, Marc-Olivier Timsit, Laurence Albiges, Stephane Oudard, Thierry Lebret, jean-Marc Treluyer, Sandra Colas, Bernard Escudier, Alain Ravaud; Department of Urology, Hôpital Européen Georges-Pompidou - Paris Descartes University, Paris, France; Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France; IUCT-Oncopôle Institut Claudius Regaud, Toulouse, France; University Hospital Pontchaillou Service d’urologie CHU Rennes, Université de Rennes, Rennes, France; Centre Alexis Vautrin, Vandoeuvre-Lès-Nancy, France; CU-PH Medical Oncology, Besançon, France; Centre Hospitalier Universitaire de Dijon, Dijon, France; Department of Urology, CHU Strasbourg, Strasbourg University, Strasbourg, France; Hopital Gabriel Montpied CHU, Clermont-Ferrand, France; Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de l'Ouest, Department of Medical Oncology, St Herblain, France; CHU Tours, Tours Cedex 9, France; Hopital Europeen Georges Pompidou, Paris, France; Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Hôpital Foch, Suresnes, France; URC/CIC Paris Descartes Necker Cochin, Paris, France; Gustave Roussy, Villejuif, France; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France

Abstract Disclosures


Background: Carmena was a randomized phase III trial, testing the benefit of CN followed by sunitinib (arm A) vs sunitinib alone (arm B), with stratification by MSKCC risk groups in 450 mRCC patients. Based on this trial, CN is not anymore recommended in mRCC (NEJM, Mejean et al, 2018). However there are questions about which patients could still benefit from CN, especially in intermediate risk group. In the present study, we investigated different subgroups from the Carmena trial to answer these questions. Methods: Carmena trial was initially stratified according to MSKCC risk groups. For the purpose of this analysis, we reclassified the patients based on IMDC risk groups. We also analyzed patients with one metastatic site vs more than one, as well as patients with secondary nephrectomy in arm B. Overall survival (OS) was the primary endpoint. Results: With a updated median FU of 61.5 months (mo), the median OS by ITT analysis was 15.6 vs 19.8 mo in arm A and B respectively stratified on MSKCC (HR 0.933 ; 95% CI [0.76- 1.15]) / stratified on IMDC (HR 0.957 ; 95% CI [0.78- 1.18]). Using IMDC risk group factors, 58.6% patients were intermediate and 41.4 % were poor risk. When looking at intermediate risk group only, 48.1% had only one risk factor (interval between diagnosis and treatment < 1y), with a median OS of 30.5 and 25.2 mo in arm A and B respectively (HR 1.24 [0.81 – 1.90]). By contrast, 51.9 % had two risk factors (mostly low hemoglobin, high corrected calcium or neutrophils), with a median OS of 16.6 and 31.2 mo in arm A and B respectively (HR 0.61 [0.41 – 0.91] p = 0.015). Regarding number of metastatic sites, 33% had only one metastatic site. Median OS was 23.6 and 22.7 mo in arm A and B respectively (HR 1.08 [0.75 – 1.57]. Finally, 40 patients had a secondary nephrectomy in arm B, with median OS of 48.5 mo [CI 95%: 27.9-64.4] vs 15.7 mo [CI 95%: 13.3-20.5] in patients who never had surgery. Conclusions: With longer FU, Carmena trial confirms that CN is not superior to sunitinib alone in ITT population, both with MSKCC and IMDC risk groups. However for patients with only one IMDC risk factor, CN might be beneficial. Number of metastatic site is not helpful to define good candidates for surgery. Finally, patients with secondary nephrectomy have very long OS, supporting this strategy. Clinical trial information: NCT00930033

Other Abstracts in this Sub-Category:


1. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Meeting: 2019 ASCO Annual Meeting Abstract No: 4500 First Author: Brian I. Rini
Category: Genitourinary (Nonprostate) Cancer - Kidney Cancer


2. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).

Meeting: 2019 ASCO Annual Meeting Abstract No: 4501 First Author: Jianjun Gao
Category: Genitourinary (Nonprostate) Cancer - Kidney Cancer


3. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Meeting: 2019 ASCO Annual Meeting Abstract No: 4502 First Author: Leonard Joseph Appleman
Category: Genitourinary (Nonprostate) Cancer - Kidney Cancer